PMID- 15693140
OWN - NLM
STAT- MEDLINE
DCOM- 20050217
LR  - 20240426
IS  - 0340-7004 (Print)
IS  - 1432-0851 (Electronic)
IS  - 0340-7004 (Linking)
VI  - 54
IP  - 1
DP  - 2005 Jan
TI  - Dendritic cells derived from metastatic cancer patients vaccinated with 
      allogeneic dendritic cell-autologous tumor cell hybrids express more CD86 and 
      induce higher levels of interferon-gamma in mixed lymphocyte reactions.
PG  - 61-6
AB  - Dendritic cells (DCs) are highly effective antigen-presenting cells that, when 
      derived from cancer patients, seem to be functionally deficient. Herein, we show 
      that vaccination with allogeneic DC-autologous tumor cell hybrids affects the 
      phenotype and improves the function of monocyte-derived DCs (Mo-DCs) from cancer 
      patients. Mononuclear cells were isolated from patients' peripheral blood by 
      density gradient centrifugation, and adherent cells were cultured in medium 
      containing GM-CSF plus IL-4 and, after 5 days, TNF-alpha. After 2 more days, 
      Mo-DCs were harvested and their CD80, CD86, and CD83 expression was assessed by 
      flow cytometry. They were also used as stimulators in mixed lymphocyte reactions 
      (MLR), where IFN-gamma production was measured by ELISA. Mo-DCs from unvaccinated 
      patients expressed significantly lower levels of CD86, and tended to express 
      lower levels of CD83 than Mo-DCs from healthy donors. However, Mo-DCs generated 
      after hybrid cell vaccination presented increased expression of the same markers 
      and induced significantly higher levels of IFN-gamma in MLR. These results 
      indicate that the use of allogeneic DC-based cancer vaccines induces recovery of 
      DC function in metastatic cancer patients and, therefore, could precede the use 
      of autologous DCs for vaccine preparation. Such an approach could be relevant and 
      should be investigated in clinical trials.
FAU - Neves, Andreia R
AU  - Neves AR
AD  - Departamento de Imunologia, ICB-USP, Av. Prof. Lineu Prestes, 1730, Sao Paulo, 
      SP, 05508-000, Brazil.
FAU - Ensina, Luis Felipe C
AU  - Ensina LF
FAU - Anselmo, Luciene B
AU  - Anselmo LB
FAU - Leite, Katia R M
AU  - Leite KR
FAU - Buzaid, Antonio C
AU  - Buzaid AC
FAU - Camara-Lopes, Luiz H
AU  - Camara-Lopes LH
FAU - Barbuto, Jose Alexandre M
AU  - Barbuto JA
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Germany
TA  - Cancer Immunol Immunother
JT  - Cancer immunology, immunotherapy : CII
JID - 8605732
RN  - 0 (Antigens, CD)
RN  - 0 (B7-2 Antigen)
RN  - 0 (CD86 protein, human)
RN  - 0 (Cancer Vaccines)
RN  - 0 (Membrane Glycoproteins)
RN  - 82115-62-6 (Interferon-gamma)
SB  - IM
MH  - Antigens, CD/*biosynthesis/genetics/immunology
MH  - B7-2 Antigen
MH  - Cancer Vaccines/immunology/*therapeutic use
MH  - Carcinoma, Renal Cell/immunology/secondary/*therapy
MH  - Cells, Cultured
MH  - Dendritic Cells/*immunology/metabolism/transplantation
MH  - Gene Expression Regulation
MH  - Humans
MH  - Hybrid Cells/immunology/*transplantation
MH  - Immunophenotyping
MH  - Interferon-gamma/*biosynthesis
MH  - Leukocytes, Mononuclear/metabolism
MH  - Lymphocyte Culture Test, Mixed/methods
MH  - Melanoma/immunology/secondary/*therapy
MH  - Membrane Glycoproteins/*biosynthesis/genetics/immunology
MH  - Neoplasm Metastasis
MH  - Phenotype
PMC - PMC11034268
EDAT- 2005/02/05 09:00
MHDA- 2005/02/18 09:00
PMCR- 2004/09/14
CRDT- 2005/02/05 09:00
PHST- 2005/02/05 09:00 [pubmed]
PHST- 2005/02/18 09:00 [medline]
PHST- 2005/02/05 09:00 [entrez]
PHST- 2004/09/14 00:00 [pmc-release]
AID - 550 [pii]
AID - 10.1007/s00262-004-0550-8 [doi]
PST - ppublish
SO  - Cancer Immunol Immunother. 2005 Jan;54(1):61-6. doi: 10.1007/s00262-004-0550-8.